You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Guanfacine

Showing 26 - 50 of 87
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Prader-Willi Syndrome Trial in New York (Placebo, Guanfacine extended release (GXR))

Withdrawn
  • Prader-Willi Syndrome
  • Placebo
  • Guanfacine extended release (GXR)
  • New York, New York
    NYU Langone Health
Aug 24, 2020

Attention Deficit Disorder With Hyperactivity Trial (SPD503 (Guanfacine HCl), Placebo)

Completed
Has Results
  • Attention Deficit Disorder With Hyperactivity
  • SPD503 (Guanfacine HCl)
  • Placebo
  • (no location specified)
May 29, 2021

Healthy Trial in Hackensack (SPD503, VYVANSE, SPD503 and VYVANSE)

Completed
Has Results
  • Healthy
  • Hackensack, New Jersey
    Advanced Biomedical Research, Inc.
Jun 10, 2021

Attention-Deficit/Hyperactivity Disorder Trial in Canada, United States (extended-release guanfacine HCl (SPD503), ,

Completed
Has Results
  • Attention-Deficit/Hyperactivity Disorder
  • extended-release guanfacine hydrochloride (SPD503)
  • +2 more
  • Little Rock, Arkansas
  • +45 more
May 14, 2021

ADHD (ADHD) Trial in Worldwide (Extended-release Guanfacine HCl (Intuniv, SPD503))

Completed
Has Results
  • Attention Deficit Hyperactivity Disorder (ADHD)
  • Extended-release Guanfacine HCl (Intuniv, SPD503)
  • Graz, Austria
  • +59 more
May 26, 2021

ADHD Trial in Worldwide (Guanfacine HCl (TAK-503), Atomoxetine HCl, Placebo)

Recruiting
  • Attention Deficit Hyperactivity Disorder
  • Guanfacine hydrochloride (TAK-503)
  • +2 more
  • Dothan, Alabama
  • +42 more
Aug 19, 2022

Attention-Deficit/Hyperactivity Disorder Trial in United States (Extended-release Guanfacine Hydrochloride, Placebo)

Completed
Has Results
  • Attention-Deficit/Hyperactivity Disorder
  • Extended-release Guanfacine Hydrochloride
  • Placebo
  • Dothan, Alabama
  • +53 more
Jun 25, 2021

Smoking Trial in New Haven (Guanfacine)

Completed
Has Results
  • Smoking
  • Guanfacine
  • New Haven, Connecticut
    Yale Center for Clinical Investigations, Yale University
Mar 4, 2020

Pervasive Development Disorders Trial in United States (, extended-release guanfacine)

Completed
Has Results
  • Pervasive Development Disorders
  • placebo
  • extended-release guanfacine
  • Los Angeles, California
  • +4 more
Mar 18, 2020

Stroke, Hemispatial Neglect Trial in London (Guanfacine, Placebo)

Completed
Has Results
  • Stroke
  • Hemispatial Neglect
  • Guanfacine
  • Placebo
  • London, United Kingdom
    Imperial College Healthcare NHS Trust
Jan 6, 2020

Attention-deficit/Hyperactivity Disorder Trial in Worldwide (Extended-release Guanfacine Hydrochloride, Placebo)

Completed
Has Results
  • Attention-deficit/Hyperactivity Disorder
  • Extended-release Guanfacine Hydrochloride
  • Placebo
  • Dothan, Alabama
  • +80 more
Jun 10, 2021

ADHD Trial in Worldwide (Extended-release Guanfacine Hydrochloride, Atomoxetine Hydrochloride, Placebo Comparator)

Completed
Has Results
  • Attention Deficit Hyperactivity Disorder
  • Extended-release Guanfacine Hydrochloride
  • +2 more
  • San Diego, California
  • +65 more
Jun 10, 2021

ACEI or ARB and COVID-19 Severity and Mortality in US Veterans

Completed
  • Hypertension
  • COVID
  • Salt Lake City, Utah
    University of Utah
Apr 26, 2021

Affective Dysregulation (AD) in ADHD Treated by Guanfacin

Unknown status
  • Affective Dysregulation
  • Guanfacine
  • (no location specified)
Apr 2, 2020

Attention Deficit/Hyperactivity Disorder Medications in Japan

Completed
  • Attention Deficit Disorder With Hyperactivity
  • MPH (Concerta)
  • +3 more
  • Titusville, New Jersey
    Janssen Investigative Site
Jan 21, 2020

Healthy Trial in Hackensack (SPD503, Concerta, SPD503 + Concerta)

Completed
Has Results
  • Healthy
  • Hackensack, New Jersey
    Advanced Biomedical Research, Inc.
Jun 10, 2021

Cannabis Dependence Trial in New York (Guanfacine)

Completed
Has Results
  • Cannabis Dependence
  • Guanfacine
  • New York, New York
    STARS
Jan 17, 2019

ADHD, Autism Spectrum Disorder Trial in Canada, United States (Randomization to either Amphetamine (AMP) class of stimulant

Not yet recruiting
  • ADHD
  • Autism Spectrum Disorder
  • Randomization to either Amphetamine (AMP) class of stimulant medication or Methylphenidate (MPH) class of stimulant medication
  • Randomization to either Alpha 2 agonist class of medication or alternate class of stimulant.
  • Irvine, California
  • +11 more
Jun 14, 2023

ADHD, Autism Spectrum Disorder Trial in Ottawa (Lisdexamfetamine Dimesylate)

Recruiting
  • Attention Deficit Hyperactivity Disorder
  • Autism Spectrum Disorder
  • Lisdexamfetamine Dimesylate
  • Ottawa, Ontario, Canada
    Center for Pediatric Excellence
Mar 28, 2022

Alcohol Withdrawal Syndrome With Alpha-2 Agonists and/or

Completed
  • Alcohol Withdrawal Syndrome
  • BZDP-Sparing Protocol
  • BZDP-Based Protocol
  • Stanford, California
    Stanford Hospital and Clinics
Jun 24, 2022

Postoperative Nausea and Vomiting, Pain, Postoperative Trial in Nashville (Guanfacine, Placebo)

Completed
Has Results
  • Postoperative Nausea and Vomiting
  • Pain, Postoperative
  • Guanfacine
  • Placebo
  • Nashville, Tennessee
    Vanderbilt University Medical Center
Dec 13, 2018

Alcohol Use Disorder Trial in Stony Brook (Dexamethasone Oral, Placebo)

Recruiting
  • Alcohol Use Disorder
  • Dexamethasone Oral
  • Placebo
  • Stony Brook, New York
    The Health Sciences Center
Jul 25, 2022

Alcohol Abstinence Trial in East Setauket, Stony Brook (Guanfacine XR 3mgs/daily, Placebo (for guanfacine))

Recruiting
  • Alcohol Abstinence
  • Guanfacine XR 3mgs/daily
  • Placebo (for guanfacine)
  • East Setauket, New York
  • +1 more
Sep 4, 2018

ADHD Trial in United States (SPD503-AM, SPD503-PM, Placebo)

Completed
Has Results
  • ADHD
  • Dothan, Alabama
  • +60 more
Jun 10, 2021

Attention Deficit Disorder Trial in Maastricht (Extended-release Guanfacine Hydrochloride (SPD503), Placebo oral capsule)

Completed
  • Attention Deficit Disorder
  • Extended-release Guanfacine Hydrochloride (SPD503)
  • Placebo oral capsule
  • Maastricht, Netherlands
    Maastricht University Medical Centre
Sep 6, 2018